Mitsutoshi Nakada

Professor
Department of Neurosurgery, Kanazawa University, Kanazawa, Japan

Mitsutoshi Nakada
Professor and Chairman
Department of Neurosurgery, Division of Neuroscience,
Graduate School of Medical Science, Kanazawa University,
13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

PROFESSIONAL BACKGROUND
April/2000 Medical Staff, Department of Neurosurgery, Kanazawa University Hospital,
April/2001 Assistant Professor, Department of Neurosurgery, Division of Neuroscience, Graduate School of Medical Science, Kanazawa University,
Oct/2002 Postdoctoral Fellow, Division of Neurology Research, Barrow Neurological Institute (BNI), St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA
May/2005 Assistant Professor, Brain Tumor Research Unit, Cancer & Cell Biology Division, TGen, The Translational Genomics Research Institute, Phoenix, Arizona, USA
April/2007 Assistant Professor, Department of Neurosurgery, Division of Neuroscience, Graduate School of Medical Science, Kanazawa University
Dec/2014 current position

Disclosure: Nothing to disclose

Presentation(s):

• ACTR-04 - BIOMARK: A phase II study of bevacizumab beyond progression for newly diagnosed glioblastoma: Safety, efficacy and prospective biomarker analysis

  Friday, November 22
  2:00 PM – 2:10 PM

• QOLP-02 - Preserving functions of language, motor, and working memory by awake mapping contributes to maintain quality of life in gliomas

  Friday, November 22
  7:30 PM – 9:30 PM

• CBMT-18 - The role of biomarker candidate gelsolin and its microRNAs in glioblastoma

  Friday, November 22
  7:30 PM – 9:30 PM

• PATH-37 - Prognostic role of TERT promoter mutations improves the stratification of IDH-mutated lower grade glioma.

  Saturday, November 23
  5:00 PM – 7:00 PM

• DDIS-05 - Identification of 2-fluoro palmitic acid as a potential therapeutic agent against glioblastoma

  Saturday, November 23
  5:00 PM – 7:00 PM

• TMOD-33 - An integrated approach combining mathematical and genomic methods to reveal the optimal timing of therapeutic intervention in WHO grade II diffuse glioma

  Saturday, November 23
  5:00 PM – 7:00 PM

• DDIS-25 - Pentamidine; a new chemotherapy targeting on glioma stem like cells

  Saturday, November 23
  5:00 PM – 7:00 PM